Bispecific antibody (BiTE)

[{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54c6/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54c6/5ba53766a928c313003d54b8.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54c5/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54c5/5ba53766a928c313003d54b8.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54c4/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54c4/5ba53766a928c313003d54b8.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54c3/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54c3/5ba53766a928c313003d54b8.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54c2/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54c2/5ba53766a928c313003d54b8.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54c1/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54c1/5ba53766a928c313003d54b8.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54c0/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54c0/5ba53766a928c313003d54b8.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54bf/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54bf/5ba53766a928c313003d54b8.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54be/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54be/5ba53766a928c313003d54b8.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54bd/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54bd/5ba53766a928c313003d54b8.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54bc/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54bc/5ba53766a928c313003d54b8.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54bb/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54bb/5ba53766a928c313003d54b8.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ba537cda928c313003d54ba/5ba53766a928c313003d54b8.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ba537cda928c313003d54ba/5ba53766a928c313003d54b8.png"}]